Clinical Trial Update: A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial comparing entrectinib with crizotinib in patients with advanced or metastatic ROS1-positive non-small cell lung cancer, with or without…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Rozlytrek (entrectinib)
• Xalkori (crizotinib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: ACTIVE_NOT_RECRUITING